急性冠脉综合征BNP和hs-CRP水平的变化及瑞舒伐他汀的干预作用

目的探讨血清脑钠肽（BNP）和高敏C反应蛋白（hs-CRP）浓度在急性冠脉综合征（ACS）中的临床意义以及瑞舒伐他汀对ACS患者BNP和hs-CRP的影响。方法选取74例ACS患者随机分为观察组和对照组,所有ACS患者均接受常规治疗,观察组加服瑞舒伐他汀治疗,疗程4周。观察并比较两组治疗前后血清BNP和hs-CRP水平。结果两组患者治疗前BNP、hs-CRP水平均明显升高,经治疗后均明显下降（P〈0.05）;与对照组治疗后比较,观察组下降更明显（P〈0.05）。结论 ACS患者血清BNP及hs-CRP水平明显升高,瑞舒伐他汀可显著降低BNP及hs-CRP水平,具有独立于降脂作用之外的抗炎作用和改善心肌缺血作用。

The level changes of acute coronary syndrome BNP and HS-CRP and the intervention of rosuvastatin

Objective To probe the clinical significance of Serum brain natriuretic peptide （ BNP） and high-sensitivity C-reactive protein （ hs-CRP） concentration in patients with acute coronary syndrome （ ACS） and the effect of rosuvastatin on patients with ACS’s BNP and hs-CRP. Methods 74 patients with ACS were randomized into two groups： the observation one and the control one. All ACS patients received conventional treatment while the patients in the observation group took rosuvastatin treatment for 4 weeks additionally. Then Observe and compare serum BNP and hs-CRP levels before and after treatment. Results The patients’BNP and hs-CRP level were significantly increased before the treatment while they were significantly decreased （ P 0. 05） after the treatment. The BNP and hs-CRP level in the observation group decreased more significantly （ P 0. 05） compared with the control group after treatment. Conclusion If ACS patients serum BNP and hs-CRP levels increase,rosuvastatin can significantly reduce levels of BNP and hs-CRP,Therefore,rosuvastatin has the effects of anti-inflammatory and improving myocardial ischemia in addition to the Lipid-lowering.